FindMyKOL
Clinical trialNCT07871552Not, yet, recruitingPhase 2Interventional

Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV

NCT07871552 is a phase 2 interventional trial sponsored by The University of Texas Health Science Center, Houston. As of 21 Nov 2026, it is not yet recruiting. It studies Continue SoC ART, Switch from an ART regimen containing lamivudine or emtricitabine + tenofovir alafenamide or tenofovir disoproxil fumarate to DOR/ISL and Switch from an nucleoside reverse transcriptase inhibitor-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL in Epigenetic Aging. The registry lists an enrollment of 60 participants at 2 sites in 1 country. The registry lists a start date of 30 Oct 2026 and a primary completion date of 15 Apr 2028. One of its registered investigators has a FindMyKOL profile.

SponsorThe University of Texas Health Science Center, HoustonEnrollment60Epigenetic Aging
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07871552
FieldValue
Registry IDNCT07871552
StatusNot yet recruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorThe University of Texas Health Science Center, Houston
Enrollment60
Registered sites2
Countries1
ConditionsEpigenetic Aging
DrugsContinue SoC ART, Switch from an ART regimen containing lamivudine or emtricitabine + tenofovir alafenamide or tenofovir disoproxil fumarate to DOR/ISL and Switch from an nucleoside reverse transcriptase inhibitor-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL
Start30 Oct 2026
Primary completion15 Apr 2028
Study completion15 Oct 2028
Last update posted23 Oct 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to quantify biologic aging (using validated epigenetic clocks) as downstream indicators of Long Interspersed Nuclear Element-1 (LINE-1) retrotransposon activity before and after switch to doravirine (DOR)/Islatravir (ISL) , to estimate whether effects of DOR/ISL on biologic aging vary by entry antiretroviral therapy (ART) regimen, and relative to continued standard of care (SoC) ART and to obtain the tolerability (adverse event profile) associated with switch to DOR/ISL relative to continued SoC ART

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Colorado, United States1 site
  • University of Colorado Anschutz Medical Center

    Aurora

Texas, United States1 site
  • the University of Texas Health Science Center at Houston

    Houston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColorado: 1 siteCO1KansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Continue SoC ARTSwitch from an ART regimen containing lamivudine or emtricitabine + tenofovir alafenamide or tenofovir disoproxil fumarate to DOR/ISLSwitch from an nucleoside reverse transcriptase inhibitor-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT07871552

Each answer restates registry values shown on this page.

What is NCT07871552?

NCT07871552 is a phase 2 interventional trial sponsored by The University of Texas Health Science Center, Houston. It studies Continue SoC ART, Switch from an ART regimen containing lamivudine or emtricitabine + tenofovir alafenamide or tenofovir disoproxil fumarate to DOR/ISL and Switch from an nucleoside reverse transcriptase inhibitor-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL in Epigenetic Aging.

Is NCT07871552 recruiting?

As of 21 Nov 2026, it is not yet recruiting.

Who leads NCT07871552?

The registry names Jordan E Lake, MD, MSc (principal investigator, The University of Texas Health Science Center, Houston) as the overall official.

Where does NCT07871552 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT07871552 study?

The registered drug and biological interventions are Continue SoC ART, Switch from an ART regimen containing lamivudine or emtricitabine + tenofovir alafenamide or tenofovir disoproxil fumarate to DOR/ISL and Switch from an nucleoside reverse transcriptase inhibitor-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL.

When is NCT07871552 expected to complete?

The registry lists a primary completion date of 15 Apr 2028 and a study completion date of 15 Oct 2028. The sponsor last updated the record on 23 Oct 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.